BELYMGO
Dead / Abandoned — Abandoned — failure to respond (as of 17 Mar 2026)
What this means for you
This application is over — abandoned 03 Mar 2026. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 99250696
- Mark type
- Stylized text
- Filed
- 24 Jun 2025
- Abandoned
- 03 Mar 2026
- Attorney of record
- Maury M Tepper III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations containing viral vectors for neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals for treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations for gene therapy, gene editing, and genome editing for treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Gene therapies, in the nature of pharmaceuticals, for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
Owner
- Sarepta Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 17 Mar 2026 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 17 Mar 2026 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 10 Nov 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 10 Nov 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 02 Sept 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 02 Sept 2025 — NON-FINAL ACTION E-MAILED
- 02 Sept 2025 — NON-FINAL ACTION WRITTEN
- 02 Sept 2025 — ASSIGNED TO EXAMINER
- 24 Jun 2025 — APPLICATION FILING RECEIPT MAILED
- 24 Jun 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 24 Jun 2025 — NEW APPLICATION ENTERED